This article is more than 5 years old. Information may no longer be current.

Drug for use in ROP vitrectomy granted orphan status

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

DUBLIN, Ireland — A plasmin-based compound for use in vitrectomy for retinopathy of prematurity has been granted orphan drug status by the Food and Drug Administration, the drug’s maker said in a press release.

According to developer ThromboGenics, based here, its drug microplasmin has shown effectiveness in inducing posterior vitreous detachment, which could be helpful during vitrectomy for retinopathy of prematurity (ROP). The company said it believes the drug can help simplify vitrectomy procedures in pediatric patients with ROP.

Microplasmin has undergone “extensive preclinical work” for intravitreal injection and has completed a successful phase 1 trial for systemic administration. The company plans to begin a phase 2a trial later this year, according to the release.